This trial demonstrates good tolerability, manageable safety, and potential efficacy of i.v. ABCB5+ MSCs as a readily available disease-modifying therapy for RDEB and provides a rationale for further clinical evaluation. The gene discussed is ABCB5; the disease is recessive dystrophic epidermolysis bullosa.